[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338441-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338441-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","in-situ-editing-of-tumour-cell-membranes-induces-aggregation-and-capture-of-pd-l1-membrane-proteins-for-enhanced-cancer-immunotherapy","In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy","","Immune checkpoint blockade shows promise for advanced cancers, but clinical use is limited by low response rates. The study presents a peptide-based biomimetic self-assembly strategy that generates a nanoparticle (TPM1) binding PD-L1 on tumour cell surfaces. TPM1 converts into in situ fibrillar networks, aggregating bound and unbound PD-L1 to block the PD-1/PD-L1 pathway, achieving prolonged tumour retention and enhanced anticancer activity in multiple mouse tumour models via reinvigoration of CD8+ T cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/in-situ-editing-of-tumour-cell-membranes-induces-aggregation-and-capture-of-pd-l1-membrane-proteins-for-enhanced-cancer-immunotherapy/338441/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/in-situ-editing-of-tumour-cell-membranes-induces-aggregation-and-capture-of-pd-l1-membrane-proteins-for-enhanced-cancer-immunotherapy/338441.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What limitation of immune checkpoint blockade motivates the study?","Question",{"text":63,"@type":64},"Clinical application is hindered by a low response rate, along with factors such as toxicity, resistance, and high cost.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does TPM1 enhance cancer immunotherapy in the tumour environment?",{"text":68,"@type":64},"TPM1 binds PD-L1 on tumour cell surfaces and transforms into in situ fibrillar networks that aggregate both bound and unbound PD-L1, blocking the PD-1/PD-L1 pathway.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports TPM1’s therapeutic potential?",{"text":72,"@type":64},"Characterizations show prolonged retention in tumours (>7 days) and anticancer effects associated with reinvigorating CD8+ T cells across multiple mouse tumour models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338441,1790458547,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-024-54081-9](https://doi.org/10.1038/s41467-024-54081-9)  \nIn situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy  \nReceived: 10 January 2024  \n\n| Accepted: 1 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nChunping Mao1,2,3,4,5,7, Fuan Deng2,7, Wanning Zhu 1,4, Leiming Xie2,  \nYijun Wang2, Guoyin Li6, Xingke Huang1,4, Jiahui Wang2, Yue Song2, Ping Zeng2, Zhenpeng He2, Jingnan Guo2, Yao Suo2, Yujing Liu2, Zhuo Chen2, Mingxi Yao2, Lu Zhang 2  & Jun Shen 1,4,5   \nImmune checkpoint blockade (ICB) therapy has emerged as a new therapeutic paradigm for a variety of advanced cancers, but wide clinical application is hindered by low response rate. Here we use a peptide-based, biomimetic, selfassembly strategy to generate a nanoparticle, TPM1, for binding PD-L1 on tumour cell surface. Upon binding with PD-L1, TPM1 transforms into ﬁbrillar networks in situ to facilitate the aggregation of both bound and unbound PDL1, thereby resulting in the blockade of the PD-1/PD-L1 pathway. Characterizations ofTPM1 manifest a prolonged retention in tumour ( > 7 days) and anticancer effects associated with reinvigorating CD8+ T cells in multiple mice tumour models. Our results thus hint TPM1 as a potential strategy for enhancing the ICB efﬁcacy.  \nImmunotherapy based on blocking programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) with immune checkpoint inhibitors (ICIs) has emerged as a new strategy for cancer therapy. This immunotherapeutic strategy has revolutionized the therapeutic paradigm in a variety of advanced cancers1. The use ofICIsto block the PD-1/PD-L1 pathway is designed to activate the host immune system to reverse immunosuppression, which is characterized by the up-regulated expression of PD-1 proteins in activated T cells, a relatively high level of PD-1 proteins on the membrane of depleted T cells, and highly expressed PD-L1 on the tumour cells membrane in the tumour immunosuppressive microenvironment2–5. The activation of the PD-1/PD-L1 pathway suppresses T cell proliferation and differentiation, leading to a decrease in the secretion of  \nimmune effector cytokines or cytotoxins6,7. In contrast, blocking PD-L1 engagement with its receptor PD-1 can effectively reverse the immunosuppression in cancers8 or autoimmune diseases9.  \nClinically, anti-PD-1 and anti-PD-L1 monoclonal antibodies (mAbs) have already been approved as ICIs in the treatment of some types of advanced cancers, such as malignant melanoma, non-small cell lung cancer, renal cell cancer, bladder cancer, and colorectal cancer, and breast cancer10–14. However, the low response rate (as low as 25% or less)15, toxicity side effects (immune-related adverse events and cardiac toxicity)16,17, drug resistance18 and high cost19 remain major hurdles forthe clinical application ofthe ICIs. These obstacles might result from the long circulation lifetime20, low tissue penetration, and degradation after endocytosis in the lysosome-associated with anti-  \n1Department of Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. 2Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, China. 3Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. 4Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. 5GBRCE for Functional Molecular Engineering, Sun YatSen University, Guangzhou, China. 6College of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, China. 7These authors contributed equally:  \nChunping Mao, Fuan Deng. e-mail: [zhanglu@sustech.edu.cn](zhanglu@sustech.edu.cn); [shenjun@mail.sysu.edu.cn](shenjun@mail.sysu.edu.cn)  \nPD-1and a","cbCaiqtIe36KCfMm","https://ap.wps.com/l/cbCaiqtIe36KCfMm","pdf",6831913,"English","# Immune checkpoint blockade background\n## Limitations of anti–PD-1/PD-L1 monoclonal antibodies\n# Peptide-based biomimetic self-assembly strategy\n## TPM1 design and PD-L1 binding\n## In situ fibrillar network formation and PD-1/PD-L1 pathway blockade\n# Experimental characterization and anticancer effects","[{\"question\":\"What limitation of immune checkpoint blockade motivates the study?\",\"answer\":\"Clinical application is hindered by a low response rate, along with factors such as toxicity, resistance, and high cost.\"},{\"question\":\"How does TPM1 enhance cancer immunotherapy in the tumour environment?\",\"answer\":\"TPM1 binds PD-L1 on tumour cell surfaces and transforms into in situ fibrillar networks that aggregate both bound and unbound PD-L1, blocking the PD-1/PD-L1 pathway.\"},{\"question\":\"What evidence supports TPM1’s therapeutic potential?\",\"answer\":\"Characterizations show prolonged retention in tumours (\\u003e7 days) and anticancer effects associated with reinvigorating CD8+ T cells across multiple mouse tumour models.\"}]","In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapy | PDF",1790023649,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/939a83ce302035ef684404de76bbbcbd.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8447a006b5bc98ffe067cb039de156ef.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d98609a350719a6f00016cc0b2e2b208.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3742d933959ca0c00dcb6ff13f6e1d68.webp",980,1301]